Knoedler, Leonard; Dean, Jillian; Diatta, Fortunay; Thompson, Noelle; Knoedler, Samuel; Rhys, Richmond; Sherwani, Khalil; Ettl, Tobias; Mayer, Simon; Falkner, Florian; Kilian, Katja; Panayi, Adriana C; Iske, Jasper; Safi, Ali-Farid; Tullius, Stefan G; Haykal, Siba; Pomahac, Bohdan; Kauke-Navarro, Martin (2024). Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions. Frontiers in immunology, 15(1372862) Frontiers Research Foundation 10.3389/fimmu.2024.1372862
|
Text
fimmu-15-1372862.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
Balancing the immune response after solid organ transplantation (SOT) and vascularized composite allotransplantation (VCA) remains an ongoing clinical challenge. While immunosuppressants can effectively reduce acute rejection rates following transplant surgery, some patients still experience recurrent acute rejection episodes, which in turn may progress to chronic rejection. Furthermore, these immunosuppressive regimens are associated with an increased risk of malignancies and metabolic disorders. Despite significant advancements in the field, these IS related side effects persist as clinical hurdles, emphasizing the need for innovative therapeutic strategies to improve transplant survival and longevity. Cellular therapy, a novel therapeutic approach, has emerged as a potential pathway to promote immune tolerance while minimizing systemic side-effects of standard IS regiments. Various cell types, including chimeric antigen receptor T cells (CAR-T), mesenchymal stromal cells (MSCs), regulatory myeloid cells (RMCs) and regulatory T cells (Tregs), offer unique immunomodulatory properties that may help achieve improved outcomes in transplant patients. This review aims to elucidate the role of cellular therapies, particularly MSCs, T cells, Tregs, RMCs, macrophages, and dendritic cells in SOT and VCA. We explore the immunological features of each cell type, their capacity for immune regulation, and the prospective advantages and obstacles linked to their application in transplant patients. An in-depth outline of the current state of the technology may help SOT and VCA providers refine their perioperative treatment strategies while laying the foundation for further trials that investigate cellular therapeutics in transplantation surgery.
Item Type: |
Journal Article (Review Article) |
|---|---|
UniBE Contributor: |
Safi, Ali-Farid |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1664-3224 |
Publisher: |
Frontiers Research Foundation |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
25 Apr 2024 11:02 |
Last Modified: |
26 Apr 2024 15:35 |
Publisher DOI: |
10.3389/fimmu.2024.1372862 |
PubMed ID: |
38650942 |
Uncontrolled Keywords: |
SOT VCA cellular therapies solid organ transplantation vascularized composite allotransplantation |
BORIS DOI: |
10.48350/196185 |
URI: |
https://boris.unibe.ch/id/eprint/196185 |
Actions (login required)
 |
Edit item |